Viramune Tablets and Oral Suspension

(contact us for more information on Viramune Tablets and Oral Suspension)
Brand NameViramune Tablets and Oral Suspension
Generic Namenevirapine
Marketed byBoehringer Ingelheim GmbH
NDA/BLA HolderBoehringer Ingelheim
NDA/BLA NumberNDA 20-636/S-027, NDA 20-933/S-017
NDA/BLA Approval Date6/21/1996, 9/11/1998
StatusApproved
Review ClassificationPriority
REMS Approval Date6/24/2008
Class REMSNo
REMS Source Document
Boxed Warning?
Boxed Warning
Indication
Route of Administration
Mechanism of Action
Risks
Risks (MedGuide Language)
Approved Labeling
Medication Guide?
Medication Guide
Medication Guide Version
Communication Plan?
Communication Plan
Elements to Assure Safe Use?
Elements to Assure Safe Use
Implementation System?
Implementation System
Assessment Program
Assessment Program Timeline
Branded Program
Program Description
Link to Branded Program
Deemed/Approved
Approval Letters

Sources

REMS Document: from FDA Approved REMS
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm

Approval Letters: from FDA Medication Guide Website
(http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.Search_Drug_Name)

Approved Labeling: from FDA Medication Guide Website
(http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.Search_Drug_Name)

Medication Guide: from FDA Medication Guide Website
(http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.Search_Drug_Name)

Previous page: REMS Directory Next page: REMS White Papers
 
Register for periodic industry updates:

2013-2014© 2014 ParagonRx. All rights reserved.